January 24, 2023
Verastem Oncology (VSTM) $60 M Private Placement Offering of Series B Convertible Preferred Stock
January 18, 2023
bluebird bio (BLUE) prices offering of 20 M shares at $6.00
December 1, 2022
RegMed investors (RMi) Research Note: Intellia Therapeutics (NTLA) prices offering of 6.25 million shares priced at $45.80
July 21, 2022
Verve Therapeutics (VERV) proposes $200 M offering priced at $27.00
July 13, 2022
Applied Genetic Technologies (AGTC) prices public offering of 16,66 M shares at $0.60
June 2, 2022
Chinook Therapeutics (KDNY) public offering of 6,4 M shares priced at $14.00 raising $105 M
March 22, 2022
Applied Genetic Technology (AGTC) prices 7.5 M share public offering
December 15, 2021
Global Blood Therapeutics (GBT) increases, prices and closes private offering of $300 million Convertible Senior Notes due 2028
April 6, 2021
Ionis Pharmaceuticals (IONS) proposed $500 million private placement of Convertible Senior Notes
March 23, 2021
Solid Biosciences (SLDB) closed 25 million share offering at $5.75
February 17, 2021
Caladrius Biosciences (CLBS) closes $65 M RDO (registered direct offering)
February 2, 2021
Pluristem (PSTI) proposes 4.76 M Registered Direct Offering (RDO) priced at $6.30
January 28, 2021
Applied Genetic Technologies (AGTC) prices 16.741 M share offering and warrants at $4.45
January 26, 2021
Precigen (PGEN) closes 17.25 M share offering at $7.50
January 25, 2021
Caladrius Biosciences (CLBS) closes $25 M Private Placement of 12.5 M shares plus warrants at a purchase price of $2.00
January 19, 2021
Editas Medicine (EDIT) proposes 3.5 million shares offering
January 12, 2021
REGENXBIO (RGNX) closes 4.26 million share offering at $47.00
January 6, 2021
Fate Therapeutics (FATE) prices 4.42 million share offering at $85.50 per share
December 15, 2020
Cellectis S.A. (CLLS) cancels $100 M ADS (American Depositary Shares) offering
December 11, 2020
Solid Biosciences (SLDB) executes a $90 M Private Placement
December 2, 2020
Intellia Therapeutics (NTLA) prices 4.79 million share offering at $36.50
November 4, 2020
Bellicum Pharmaceuticals (BLCM) closes 1.04 M share offering
August 12, 2020
Adverum Biotechnologies (ADVM) closes $216.8 million offering priced at $3.00
July 8, 2020
BioLife Solutions (BLFS) closes 5.95 million share offering priced at $14.50
July 2, 2020
MiMedx Group (OTC PINK: MDXG closed $150 million private equity and debt financings
5 hours 47 min ago
RegMed Investors (RMi) Closing Bell: although early, snorkel for bottom values
13 hours 56 min ago
RegMed Investors’ (RMi) pre-open: when markets get wasted
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.